BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home » Blogs » BioWorld Perspectives » Caught in Its Own Snare

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

Caught in Its Own Snare

July 16, 2012
By Mari Serebrov

A hunter walks into a bar and says, “Did you hear the one about the FDA?”

“You mean the time it shot itself in the foot?” the bartender responds.

“The left foot or the right foot?” another hunter asks, wiping the beer froth from his mouth.

“What difference does that make?” the first hunter asks.

“I want to know if it’s the one I’ve heard before. Or if this is a new one.”

The first rule of thumb for hunters is to know what they’re doing. Otherwise, they might shoot themselves in the foot – or worse. The second is to get a valid hunting license. The third is to make sure they don’t target animals that aren’t in season.

The FDA broke those rules when it set out to track down a few scientists who it claimed had gone rogue by sharing concerns about device approvals with members of Congress and the White House. The agency tried to get a license. “No way,” it was told by the Office of Inspector General. “That dog just won’t hunt.”

The FDA, being the FDA, decided it didn’t need a license. It loaded its guns, set its snares and hired a document-hunting outfitter to help it bag its trophies. The agency reportedly gave the guide a list of the targeted species and provided scents to sniff out along the document trail. Those smells led to the media and a few hound dog congressmen and their staffs – species that should be on every federal agency’s “do not hunt” list.

The hunters at the FDA justified their poaching by saying the scientists were fair game because they were leaking information, some of which could be proprietary. Those leaks could damage the agency, its mission and its reputation, they reasoned.

Intent on catching the big game and defending its unlicensed hunt, the FDA forgot to set the safety on its weapons. As a result, the outfitter tripped and misfired, publicly posting a database with the contents of all the document tracking, including the proprietary stuff and the scents used to mark the trail. The shot hit the FDA square in the mouth and left a gaping, oozing wound in its reputation.

Now, the FDA’s the prey. And these days, it’s looking a lot like a limping deer caught in the intensely hot headlights of Congress and the media.

Popular Stories

  • Today's news in brief

    BioWorld
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of Alzheimer's disease in the brain

    ADPD 2026: Three inflection points to target Alzheimer’s disease

    BioWorld Science
    A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

    BioWorld Science
    At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing